These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 24663014

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.
    Kwara A, Yang H, Antwi S, Enimil A, Gillani FS, Dompreh A, Ortsin A, Opoku T, Bosomtwe D, Sarfo A, Wiesner L, Norman J, Alghamdi WA, Langaee T, Peloquin CA, Court MH, Greenblatt DJ.
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397066
    [Abstract] [Full Text] [Related]

  • 3. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    Bonnet M, Bhatt N, Baudin E, Silva C, Michon C, Taburet AM, Ciaffi L, Sobry A, Bastos R, Nunes E, Rouzioux C, Jani I, Calmy A, CARINEMO study group.
    Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
    [Abstract] [Full Text] [Related]

  • 4. Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.
    Bhatt NB, Baudin E, Meggi B, da Silva C, Barrail-Tran A, Furlan V, Grinsztejn B, Bonnet M, Taburet AM, ANRS 12146/12214-CARINEMO Study Group.
    J Antimicrob Chemother; 2015 Jan; 70(1):225-32. PubMed ID: 25239466
    [Abstract] [Full Text] [Related]

  • 5. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, Prommool V, Ruxrungtham K, N2R Study Team.
    Clin Infect Dis; 2009 Jun 15; 48(12):1752-9. PubMed ID: 19438397
    [Abstract] [Full Text] [Related]

  • 6. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
    Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S.
    Antimicrob Agents Chemother; 2013 Feb 15; 57(2):1019-24. PubMed ID: 23254426
    [Abstract] [Full Text] [Related]

  • 7. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
    Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, Goemaere E, Coetzee D, Maartens G.
    JAMA; 2008 Aug 06; 300(5):530-9. PubMed ID: 18677025
    [Abstract] [Full Text] [Related]

  • 8. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH, Mtabho CM, Fillekes Q, van den Boogaard J, Kisonga RM, Mleoh L, Ndaro A, Kisanga ER, van der Ven A, Aarnoutse RE, Kibiki GS, Boeree MJ, Burger DM.
    Antivir Ther; 2013 Aug 06; 18(1):105-13. PubMed ID: 23043067
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study.
    Sinha S, Raghunandan P, Chandrashekhar R, Sharma SK, Kumar S, Dhooria S, Ekka M, Velpandian T, Ranjan S, Ahmad H, Samantaray JC, Venkatesh S, Rewari BB, Khan NH, Pandey RM.
    BMC Infect Dis; 2013 Oct 17; 13():482. PubMed ID: 24134449
    [Abstract] [Full Text] [Related]

  • 11. Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.
    Bertrand J, Verstuyft C, Chou M, Borand L, Chea P, Nay KH, Blanc FX, Mentré F, Taburet AM, CAMELIA (ANRS 1295-CIPRA KH001) Study Group.
    J Infect Dis; 2014 Feb 01; 209(3):399-408. PubMed ID: 23990572
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
    Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, Supparatpinyo K, Mohapi L, Gupta A, Benson CA, Kim P, Fletcher CV, AIDS Clinical Trials Group A5279 Study Team.
    Clin Infect Dis; 2015 Oct 15; 61(8):1322-7. PubMed ID: 26082504
    [Abstract] [Full Text] [Related]

  • 14. Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.
    Chirehwa MT, McIlleron H, Wiesner L, Affolabi D, Bah-Sow O, Merle C, Denti P, RAFA team.
    J Antimicrob Chemother; 2019 Jan 01; 74(1):139-148. PubMed ID: 30239829
    [Abstract] [Full Text] [Related]

  • 15. Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy.
    Padmapriyadarsini C, Bhavani PK, Tang A, Kumar H, Ponnuraja C, Narendran G, Hannah E, Ramesh C, Chandrasekar C, Wanke C, Swaminathan S.
    Int J Infect Dis; 2013 Dec 01; 17(12):e1154-9. PubMed ID: 24120216
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R, Musaazi J, Denti P, Aber F, Lamorde M, Dooley KE, Aarnoutse R, Sloan DJ, Sekaggya-Wiltshire C.
    Trials; 2020 Feb 13; 21(1):181. PubMed ID: 32054536
    [Abstract] [Full Text] [Related]

  • 17. Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.
    Kwara A, Ramachandran G, Swaminathan S.
    Expert Opin Drug Metab Toxicol; 2010 Jan 13; 6(1):55-68. PubMed ID: 19968575
    [Abstract] [Full Text] [Related]

  • 18. CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
    Manosuthi W, Sukasem C, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S.
    Antimicrob Agents Chemother; 2014 Jan 13; 58(4):2268-73. PubMed ID: 24492364
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
    Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas S, Menon PA, Selvaraju S, Pooranagangadevi NP, Bhavani PK, Ponnuraja C, Dilip M, Ramachandran R.
    Clin Infect Dis; 2011 Oct 13; 53(7):716-24. PubMed ID: 21890776
    [Abstract] [Full Text] [Related]

  • 20. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
    Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Kumar P, Ramesh K, Anitha S, Narendran G, Menon P, Gomathi C, Swaminathan S.
    Antimicrob Agents Chemother; 2009 Mar 13; 53(3):863-8. PubMed ID: 19124658
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.